143 related articles for article (PubMed ID: 26354928)
21. Number of satellite nevi as a correlate for neurocutaneous melanocytosis in patients with large congenital melanocytic nevi.
Marghoob AA; Dusza S; Oliveria S; Halpern AC
Arch Dermatol; 2004 Feb; 140(2):171-5. PubMed ID: 14967788
[TBL] [Abstract][Full Text] [Related]
22. Drug combo shows promise in NRAS-mutant melanoma.
Cancer Discov; 2014 Aug; 4(8):OF2. PubMed ID: 25092757
[No Abstract] [Full Text] [Related]
23. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
24. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
[No Abstract] [Full Text] [Related]
25. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
26. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
27. Nevomelanocytic proliferations in the central nervous system of children.
Reyes-Mugica M; Chou P; Byrd S; Ray V; Castelli M; Gattuso P; Gonzalez-Crussi F
Cancer; 1993 Oct; 72(7):2277-85. PubMed ID: 8374887
[TBL] [Abstract][Full Text] [Related]
28. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis.
Shih F; Yip S; McDonald PJ; Chudley AE; Del Bigio MR
Acta Neuropathol Commun; 2014 Oct; 2():140. PubMed ID: 25330907
[TBL] [Abstract][Full Text] [Related]
30. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
[TBL] [Abstract][Full Text] [Related]
31. Searching for the Chokehold of NRAS Mutant Melanoma.
Posch C; Vujic I; Monshi B; Sanlorenzo M; Weihsengruber F; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Jul; 136(7):1330-1336. PubMed ID: 27160069
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
33. Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis.
Takahashi H; Natsumeda M; Hara N; Koyama A; Shimizu H; Miyashita A; Satake D; Mouri Y; Tsukano J; Kawabe K; Tsukamoto Y; Okada M; Ogura R; Yuki A; Umezu H; Kakita A; Ikeuchi T; Oishi M
Acta Neuropathol Commun; 2024 Jan; 12(1):14. PubMed ID: 38254245
[TBL] [Abstract][Full Text] [Related]
34. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
[TBL] [Abstract][Full Text] [Related]
35. In vivo antitumoral effect of 4-nerolidylcatechol (4-NC) in NRAS-mutant human melanoma.
Alves-Fernandes DK; Oliveira ÉA; Hastreiter AA; Faião-Flores F; Felipe-Silva AS; Turato W; Fock RA; Maria-Engler SS; Barros SBM
Food Chem Toxicol; 2020 Jul; 141():111371. PubMed ID: 32334110
[TBL] [Abstract][Full Text] [Related]
36. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
[TBL] [Abstract][Full Text] [Related]
37. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
Akabane H; Sullivan RJ
Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
[TBL] [Abstract][Full Text] [Related]
38. Binimetinib in heavily pretreated patients with NRAS-mutant melanoma with brain metastases.
Goldinger SM; Valeska Matter A; Urner-Bloch U; Narainsing J; Micaletto S; Blume I; Mangana J; Dummer R
Br J Dermatol; 2020 Feb; 182(2):488-490. PubMed ID: 31436845
[No Abstract] [Full Text] [Related]
39. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
[TBL] [Abstract][Full Text] [Related]
40. Mutated and amplified NRAS in a subset of cutaneous melanocytic lesions with dermal spitzoid morphology: report of two pediatric cases located on the ear.
Dubruc E; Balme B; Dijoud F; Disant F; Thomas L; Wang Q; Pissaloux D; de la Fouchardiere A
J Cutan Pathol; 2014 Nov; 41(11):866-72. PubMed ID: 25263998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
